The Deepening Opioid Crisis in North America: Historical Context and Current Solutions
- 222 Downloads
Purpose of Review
The purpose of this review is to (1) detail the historical context behind the rise of opioid use disorder (OUD) and opioid-related harms in the United States (US) and Canada, (2) describe the epidemiology of OUD in these two countries, and (3) discuss current strategies being employed to address this public health emergency in North America.
Opioid-related overdose has become a leading cause of unintentional injury related death in North America. Deaths have risen in parallel with opioid prescribing and the rising prevalence of unintentional exposure to highly potent synthetic opioids. At the same time, rates of injection drug use-related infections such as hepatitis C and endocarditis have also increased.
Both Canada and the US have implemented policy changes and interventions at the national and local levels in an attempt to stem rising opioid attributable morbidity and mortality. In many settings, the collective goal has been to increase access to treatment of OUD, expand harm reduction interventions (including improved access to naloxone), and develop and disseminate guidelines on the safe prescribing of opioids for non-cancer pain and the management of OUD.
KeywordsOpioid Addiction Overdose North America Fentanyl Heroin
M. Eugenia Socias is supported by a Michael Smith Foundation for Health Research (MSFHR)/St Paul’s Foundation Scholar Award.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 1.Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts: National Center for Health Statistics; 2018 [cited February 18, 2018]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
- 2.Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: apparent opioid-related deaths in Canada (January 2016 to September 2017) Web-based report. Ottawa: Public Health Agency of Canada; 2018. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-march-2018.html. Accessed 29 March 2018Google Scholar
- 3.Centers for Disease Control and Prevention. Annual Surviellance Report of Drug-Related Risks and Outcomes- United States, 2017. Surveillance Special Report 1: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2017. Available from: https://www.cdc.gov/drugoverdose/pdf/pubs/2017cdc-drug-surveillance-report.pdf. Accessed 12 March 2018
- 6.• Murphy Y, Goldner EM, Fischer B. Prescription opioid use, harms and interventions in Canada: a review update of new developments and findings since 2010. Pain Physician. 2015;18(4):E605–14 This narrative review synthesized key information on prescription opioid dispensing, non medical use, related-harms, interventions and impacts in Canada between 2010 and 2015. PubMedPubMedCentralGoogle Scholar
- 10.Quinones S. Dreamland: the true tale of America’s opiate epidemic. New York: Bloomsbury Press; 2015. 374 pGoogle Scholar
- 12.United States of America v. The Purdue Frederick Company, Inc., et al. Hearing before the US District Court for the Western District of Virginia. 2007.Google Scholar
- 13.OxyContin and OxyNEO national settement agreement 2018. Available from: https://www.wagners.co/current-class-actions/oxycontin/. Accessed 28 May 2018
- 17.A consensus statement from the American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic pain. Clin J Pain. 1997;13(1):6–8.Google Scholar
- 18.Ornstein C, Weber T. American pain Foundation shuts down as senators launch investigation of prescription narcotics: ProPublica; 2012. Available from: https://www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups.
- 21.U.S. Prescribing Rate Maps: Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html. Accessed on 24 June 2018
- 22.Overdose Death Rates: National Institute on Drug Abuse. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 24 June 2018
- 24.National report: Apparent opioid-related deaths in Canada (released June 2018): Public Health Agency of Canada; 2018. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/national-report-apparent-opioid-related-deaths-released-june-2018.html. Accessed 20 June 2018.
- 25.Canadian Institute for Health Information. Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. Ottawa: CIHI; 2017.Google Scholar
- 26.International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2018; statistics for 2016. New York: United Nations; 2017.Google Scholar
- 30.Health Canada. Canadian tobacco, alcohol and drugs survey (CTADS): 2015 summary2017 March 14, 2018. Available from: https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2015-summary.html.
- 31.Luce J, Strike C. A cross-Canada scan of methadone maintenance treatment policy developments. A report prepared for the Canadian executive council on addictions. 2011.Google Scholar
- 33.U.S. Department of Health and Human Services. About the U.S. Opioid Epidemic: U.S. Department of Health and Human Services. 2018. Available from: https://www.hhs.gov/opioids/about-the-epidemic/. Accessed 8 March 2018
- 37.Henry J Kaiser Family Foundation:Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). Available from: https://www.kff.org/other/state-indicator/opioid-overdose-death-rates/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Opioid%20Overdose%20Death%20Rate%20(Age-Adjusted)%22,%22sort%22:%22desc%22%7D. Accessed 26 June 2018
- 40.• O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700 - 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–202. This study highlights the rising contribution of fentanyl and fentanyl analogs to the drug overdose death rate in the United States.PubMedPubMedCentralCrossRefGoogle Scholar
- 41.• Hayashi K, Milloy MJ, Lysyshyn M, DeBeck K, Nosova E, Wood E, et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1–6. This study documented high prevalence of exposure to fentanyl among people who inject drugs, with the majority of participants being unaware of this exposure. PubMedPubMedCentralCrossRefGoogle Scholar
- 54.Canadian Institute for Health Information. Opioid-related harms in Canada. Ottawa: CIHI; 2017.Google Scholar
- 58.U.S. Department of Health and Human Services. Opioid abuse in the U.S. and the HHS actions to address opioid-drug related overdoses and death 2015. Available from: https://aspe.hhs.gov/basic-report/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-overdoses-and-deaths. Accessed 18 April 1018
- 59.Comprehensive Addiction and Recovery Act of 2016. Available from: https://www.govtrack.us/congress/bills/114/s524/text. Accessed on une 23 2018
- 61.•• Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Reports of the Surgeon General. Washington (DC); 2016. This comprehensive report summarizes the chronic disease model of addiction and reviews evidence based approaches to addiction mangement.Google Scholar
- 63.Gomes T, Mastorakos A, Paterson JM, Sketris I, Caetano P, Greaves S, et al. Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. CMAJ Open. 2017;5(4):E800–E7.PubMedPubMedCentralCrossRefGoogle Scholar
- 66.Health Canada. Government of Canada: actions on Opiods, 2016 and 2017. Ottawa: Health Canada; 2017.Google Scholar
- 67.•• Bruneau J, Ahamad K, Goyer ME, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E57 This is the first-ever Canadian evidence-based guideline for the management of opioid use disorder. The guideline supports a stepped and integrated care approach, where treatment intensity is continually adjusted to match individual patient needs over time. PubMedPubMedCentralCrossRefGoogle Scholar
- 70.•• Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783–90. This is one of the first studies to systematically evaluate the literature regarding the relationship between prescription drug monitoring programs and overdose rates in the United States. PubMedPubMedCentralCrossRefGoogle Scholar
- 76.Lysyshyn M, Dohoo C, Forsting S, Kerr T, McNeil R. Evaluation of a fentanyl drug checking program for clients of a supervised injection site, Vancouver, Canada. Montreal: Harm Reduction International; 2017.Google Scholar
- 77.Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder. Vancouve: BC Centre on Substance Use; 2017 [cited 2018 March 21]. Available from: http://www.bccsu.ca/wp-content/uploads/2017/10/BC-iOAT-Guidelines-10.2017.pdf.
- 78.B.C. nurse practitioners can now prescribe drugs for opioid addiction. Vancouver Sun. 2018 (col. 2018).Google Scholar
- 82.Hering R, Lefebvre L, Stewart P, Selby P. Increasing addiction medicine capacity in Canada: the case for collaboration in education and research. Can J Addict. 2014;5(3):10–4.Google Scholar